AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Secombes et al.				Docket No. ABLE-0021	
Filing Date	Examiner	Customer	No.	Group Art Unit	t Confirmation No.
July 22, 2002	Robert M. Kelly	26259		1633	9521
COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
CLAIMS REMAINING	HIGHEST #	NUMBER EXTRA		DATE	ADDITIONAL
AFTER AMENDMENT	PREV. PAID FOR	CLAIMS PRESENT	\perp		FEE
3 -	52 =	0	х	\$50.00	\$0.00
1 -	4 =	0	×	\$200.00	\$0.00
nt Claims (check if app	licable) 🗆				\$0.00
	TOTAL ADDITIONAL F	FEE FOR THIS AN	JEN	DMENT	\$0.00
No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. □ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 50-1619 □ Any additional filing fees required under 37 C.F.R. 1.16. □ Any patent application processing fees under 37 CFR 1.17. □ Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Mathlee A. Tyrrell P.C.					
rell (/ /		the United States	Posta	al Service with suf	fficient postage as first
	Filing Date July 22, 2002 NOCLONAL ANTIBOD with is an amendment in calculated and is trans CLAIMS REMAINING AFTER AMENDMENT 3 - 1 - nt Claims (check if apple) conal fee is required for a marge Deposit Account In the amount of cotor is hereby authorized cation or credit any ove additional filing fees receptatent application proceed by credit card. Form PT G: Information on this on this form. Provide	Filing Date Examiner July 22, 2002 Robert M. Kelly NOCLONAL ANTIBODY 3F1H10 NEUTRALI COMMISSIONER FO with is an amendment in the above-identified a calculated and is transmitted as shown below. CLAIMS AS AM CLAIMS REMAINING HIGHEST # AFTER AMENDMENT PREV. PAID FOR 3 - 52 = 1 - 4 = nt Claims (check if applicable) TOTAL ADDITIONAL F conal fee is required for amendment. narge Deposit Account No. in the amount of to cover the filing extern is hereby authorized to charge payment of cation or credit any overpayment to Deposit Account or credit any overpayment to Deposit Account additional filing fees required under 37 C.F.R. patent application processing fees under 37 Cl by credit card. Form PTO-2038. S: Information on this form may become puron this form. Provide credit card information	Filing Date Examiner Customer July 22, 2002 Robert M. Kelly 26259 NOCLONAL ANTIBODY 3F1H10 NEUTRALISING VHSV COMMISSIONER FOR PATENTS: with is an amendment in the above-identified application. calculated and is transmitted as shown below. CLAIMS AS AMENDED CLAIMS REMAINING HIGHEST # NUMBER EXTRA AFTER AMENDMENT PREV. PAID FOR CLAIMS PRESENT 3 - 52 = 0 1 - 4 = 0 Int Claims (check if applicable) TOTAL ADDITIONAL FEE FOR THIS AMENDED TOTAL ADDITIONAL FEE FOR THIS AMENDED	Filing Date July 22, 2002 Robert M. Kelly COMMISSIONER FOR PATENTS: with is an amendment in the above-identified application. calculated and is transmitted as shown below. CLAIMS AS AMENDED CLAIMS REMAINING AFTER AMENDMENT PREV. PAID FOR AFTER AMENDMENT TOTAL ADDITIONAL FEE FOR THIS AMENDED TOTAL ADDITIONAL FEE FOR THIS AMENDED TOTAL ADDITIONAL FEE FOR THIS AMENDED Conal fee is required for amendment. In the amount of to cover the filing fee is enclosed. Stor is hereby authorized to charge payment of the following fees association or credit any overpayment to Deposit Account Solutional filing fees required under 37 C.F.R. 1.16. patent application processing fees under 37 CFR 1.17. by credit card. Form PTO-2038. Signormation on this form may become public. Credit card informon this form. Provide credit card information and authorization of the content of the form. Provide credit card information and authorization of the form. Provide credit card information and authorization of the form. Provide credit card information and authorization of the form. Provide credit card information and authorization of the form. Provide credit card information and authorization of the form. Provide credit card information and authorization of the form. Provide credit card information and authorization of the form.	Filing Date Examiner Customer No. Group Art Unit July 22, 2002 Robert M. Kelly 26259 1633 NOCLONAL ANTIBODY 3F1H10 NEUTRALISING VHSV COMMISSIONER FOR PATENTS: with is an amendment in the above-identified application. calculated and is transmitted as shown below. CLAIMS AS AMENDED CLAIMS REMAINING HIGHEST # NUMBER EXTRA RATE AFTER AMENDMENT PREV. PAID FOR CLAIMS PRESENT 3 - 52 = 0 x \$50.00 1 1 - 4 = 0 x \$200.00 Int Claims (check if applicable) TOTAL ADDITIONAL FEE FOR THIS AMENDMENT onal fee is required for amendment. large Deposit Account No. in the amount of to cover the filling fee is enclosed. Stor is hereby authorized to charge payment of the following fees associated with this cation or credit any overpayment to Deposit Account 50-1619 additional filling fees required under 37 C.F.R. 1.16. patent application processing fees under 37 CFR 1.17. by credit card. Form PTO-2038. 3: Information on this form may become public. Credit card information should on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

ABLE-0021

Inventors:

Secombes et al.

Serial No.:

10/088,780

Filing Date:

July 22, 2002

Examiner:

Kelly, Robert M.

Customer No.:

26259

Group Art Unit:

1633

Confirmation No.:

9521

Title:

Monoclonal Antibody 3F1H10

Neutralising VHSV

Electronically Submitted via EFS-Web

Date: January 5, 2007

I hereby certify that this paper is being electronically submitted on the date indicated above to the Commissioner for Patents, U.S. Patent & Trademark Office (Fee Amendment).

Typed Name: KAthleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents

U.S. Patent & Trademark Office

Dear Sir:

Reply under 37 C.F.R. 1.116

This is a reply to the Office Action mailed October 5, 2006 setting a three (3) month statutory period for response. Please enter the following amendments and remarks into the record.

Attorney Docket No.: ABLE-0021

Inventors:

Secombes et al.

Amendments to the claims are reflected in the listing

Serial No.: Filing Date:

10/088,780 July 22, 2002

Page 2

of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 5.